Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 9/20 | 1.00 |
| ▸ | CES2 | O00748 | 5/20 | 1.00 |
| ▸ | CES1 | P23141 | 5/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | AKR1B10 | O60218 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PRKCH | P24723 | 1/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PTPN11 | Q06124 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.76 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enoxolone SCHEMBL15448799 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL11891060 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL13382933 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL2762655 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL23016683 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL25465 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL23252837 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL2762929 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL6544340 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 | |
| Enoxolone SCHEMBL4916952 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2CES2CES1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119656062-A | Composition for protecting cells from oxidative and mitochondrial stresses | 努其杜有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-12178846-B2 | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-12-31 | — | — | US | claimed |
| CN-112423726-B | Composition for protecting cells from oxidative and mitochondrial stresses | 努其杜有限公司 | 2024-12-27 | — | — | CN | claimed |
| CN-118105365-A | Use of a compound in the manufacture of a medicament for preventing or treating idiopathic vomiting in a companion animal | 马斯公司 | 2024-05-31 | — | — | CN | claimed |
| CN-110713512-B | Isopropanolamine substructure-containing glycyrrhetinic acid piperazine compounds and preparation method and application thereof | 贵州大学 | 2022-09-27 | — | — | CN | claimed |
| US-11077080-B2 | Use of anti-connexin agents for modulating the therapeutic effect of psychotropic drugs | COMMISSARIAT A L'ENERGIE ATOMIQUE AUX ENERGIES ALTERNATIVES (FR) | 2021-08-03 | — | — | US | claimed |
| CN-108732278-B | Method for simultaneously determining ten natural sweeteners in beverage by high performance liquid chromatography | 山东省食品药品检验研究院 | 2021-06-01 | — | — | CN | claimed |
| CN-112423726-A | Compositions for protecting cells from oxidative and mitochondrial stress | 努其杜有限公司 | 2021-02-26 | — | — | CN | claimed |
| EP-2986136-B1 | COMPOSITION AND METHOD FOR PREVENTING, REDUCING, ALLEVIATING, OR TREATING IDIOPATHIC VOMITING | MARS INC (US) | 2020-08-12 | — | — | EP | claimed |
| US-10548935-B2 | Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting | MARS, INCORPORATED (US) | 2020-02-04 | — | — | US | claimed |
| US-6703536-B2 | ENZYME INHIBITOR IS TRANSFERRED TO SKIN WITH SKIN CARE COMPOSITION AND IS AVAILABLE AT SKIN/URINE AND SKIN/FECES INTERFACES TO INHIBIT ENZYMATIC ACTIVITY ON SKIN AND TO REDUCE OR PREVENT OCCURRENCE OF INFLAMMATION | THE PROCTER & GAMBLE COMPANY | 2004-03-09 | — | — | US | claimed |
| US-20030139711-A1 | Disposable absorbent article having a skin care composition containing an enzyme inhibitor | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
| US-20030134761-A1 | Foaming composition based on silica and on cationic polymer | L'OREAL (FR) | 2003-07-17 | — | — | US | claimed |
| US-20030007988-A1 | Slimming cosmetic composition comprising a plant extract containing a plant natriuretic peptide (PNP) | LABORATOIRES CLARINS | 2003-01-09 | — | — | US | claimed |
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | L'OREAL S.A. (FR) | 2002-04-11 | — | — | US | claimed |
| US-20020034480-A1 | Make-up compositions comprising a binder phase, and make-up methods | L'OREAL, S.A. (FR) | 2002-03-21 | — | — | US | claimed |
| EP-1061962-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | claimed |
| WO-1999045973-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0285367-B1 | PHARMACEUTICAL COMPOSITION | Temple University of the Commonwealth System of Higher Education (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0285367-A2 | Pharmaceutical composition | Temple University of the Commonwealth System of Higher Education (US) | 1988-10-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020034480-A1 | Make-up compositions comprising a binder phase, and make-up methods | TTR, GRN, MB | HSD11B1 1718/4885HSD11B2 1886/4885CES2 4712/4885 |
| US-20030134761-A1 | Foaming composition based on silica and on cationic polymer | SGMS1, SMURF1, PITHD1 | HSD11B1 2572/4885HSD11B2 2855/4885CES2 2522/4885 |
| US-20020041854-A1 | Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods | CUTA, LAGE3, MITF | HSD11B1 1920/4885HSD11B2 2241/4885CES2 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.